|
FUJIFILM Biotechnologies is proud to be an innovative CDMO partner, seamlessly guiding our customers though their journey of creating life-impacting medicines from initial process development stages through to full commercial supply. Catch up on our latest news and insights below.
|
|
|
Fujifilm Showcases Global Capabilities, Deepens Partnerships at BIO International
|
|
The FUJIFILM Biotechnologies team returned energized from another incredible BIO International Convention in San Diego. Connecting with partners, clients, and innovators across the global biopharma community, our team had meaningful conversations that reinforced why we attend events like BIO year after year.
As a leading CDMO specializing in microbial and mammalian biologics and cell & gene therapies, BIO gave us the perfect opportunity to highlight the momentum we have been building in our global network over the past year, from our newly opened commercial-scale facility in North Carolina, USA to our recent manufacturing and process development expansion in Billingham, UK and new QC lab in Hillerød, Denmark.
A standout moment from the show was welcoming John Crowley, President & CEO of BIO, to the Fujifilm booth,
where he engaged directly with our leadership team, shared insights on the strategic priorities of the BIO organization, and learned more about Fujifilm's expanding role in the biopharma industry.
It was a tremendous opportunity to share our vision as Partners for Life together with the entire Fujifilm Life Sciences group and explore new collaborations that will help supply life impacting medicines for patients throughout the world.
Thank you to everyone who stopped by. We look forward to what’s ahead.
|
|
|
Viral Vector CDMO Capabilities
|
|
Get a behind the scenes look at our viral vector CDMO facility in College
Station, Texas, USA.
|
|
|
| Discover our approach to viral vector manufacturing and scale-up for gene therapies.
|
|
|
| Explore insights to de-risk development and maximize CDMO value for your gene therapy.
|
|
|
- Toshihisa "Toshi" Iida, Board Director, General Manager, Life Sciences Headquarters, FUJIFILM Corporation & Chairman, FUJIFILM Biotechnologies, breaks down top opportunities, challenges, and trends currently facing the life science industry in a pre-BIO 2026 interview with Pharma Navigator. Watch interview →
- Lars Petersen, CEO, FUJIFILM Biotechnologies, examines the Fujifilm transformation, leadership lessons, and the future of the kojoX™ network in Why FUJIFILM Biotechnologies Thinks the CDMO Model is Broken for the Making it in Manufacturing podcast. Listen to podcast →
- Helen Bickley, Chief Quality Officer, FUJIFILM Biotechnologies, discusses our flexible, future-ready approach to our facility design,
focused on protecting quality and patient safety with European Pharmaceutical Review. Read the full article →
- Lauren Collison, Ph.D., Global Head of Viral Gene Therapy Business Unit, shares her insights on how the increasing complexity in cell & gene therapy is redefining CDMO differentiation in Pharma Almanac's industry roundtable. Read the full article →
- Katherine Schewe, Director, Strategic Accounts, Advanced Therapies, outlines the critical role of CDMOs as strategic partners for cell and gene therapies, and key considerations for developers when selecting a CDMO in a recent Contract Pharma article. Read the full article →
|
|
September 22-25, 2026 | Boston, MA | Booth 1030
|
|
Be sure to connect with our technical experts during BPI to discuss your mammalian and microbial biologics development and manufacturing needs and explore how we can help advance your program and secure your supply. Visit us at booth 1030 or schedule a meeting today.
Don’t miss the opportunity to learn more about our monoclonal antibody (mAb) formulation capabilities. Join Christopher Marlein, Sr. Principal Scientist, on September 23rd at 3:00 pm as he presents A Toolbox for Success: Processing and Formulating High-Concentration mAbs.
Learn More →
|
|
|
|
|
